|Phone||+49 6132 77 8740|
Our primary aim is to activate success for those companies and entrepreneurs we support and to earn a reputation as a long-term trusted partner. Beyond capital investment, we intend to take an active role with our portfolio companies – delivering significant added value through our own extensive drug discovery, scientific and managerial expertise and access to selected relevant experts and knowledge. Nevertheless, we also attach significant importance to confidentiality, establishing ethical walls to protect our portfolio companies and entrepreneurs.
Our sole focus is to search for significant enhancements in patient care through innovative and pioneering science including (but not limited to):
These extend the current therapeutic area focus of Boehringer Ingelheim and demonstrate our commitment to investigate new treatment modalities and technologies, beyond our existing landscape, for the potential future benefit of patients.
|Hookipa Biotech||11/2013||Series B||€20M||5|
|ArmaGen Technologies||11/2012||Series A||$17M||4|
|Promethera Biosciences||3/2012||Series B||€23.6M||3|